ArticleCureus2025
Safety of Hydroxychloroquine for COVID-19 Prophylaxis in Healthcare Workers: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn March 2020, the World Health Organization (WHO) declared SARS-CoV-2 a pandemic after identifying it as the causative agent of COVID-19. Hydroxychloroquine (HCQ) was widely used as a prophylactic measure among healthcare workers (HCWs). However, its use as a preventive medication in asymptomatic individuals, particularly given its known adverse effect profile, remains relatively unexplored. This study aimed to evaluate the safety of HCQ prophylaxis among HCWs in Mumbai, India. MATERIALS AND
methodsA survey-based, cross-sectional study was conducted using a self-designed questionnaire distributed to HCWs in Mumbai who had direct or indirect patient contact and were taking HCQ for COVID-19 prevention.
resultsA total of 125 responses were collected, with males accounting for 80 (64%) of the participants. The majority of HCWs had a medical doctor background, and the mean age was 41.8 years. Thirty-eight HCWs (30.4%) reported frequent exposure to COVID-19, while 106 (84.8%) had direct patient contact. A minority (34 participants, 27.2%) received HCQ prophylaxis for seven weeks, and 123 (98.4%) adhered to the standard prophylactic regimen. Comorbidities were present in 27 (21.6%) HCWs, with hypertension (19, 15.2%) being the most common. Among the participants, 64 (51.2%) underwent an electrocardiogram (ECG) before prophylaxis, while 56 (44.8%) had follow-up ECGs. Adverse effects were reported by 44 (35.2%) HCWs, with a statistically significant higher incidence among females. The most common adverse effects were gastrointestinal symptoms (48, 38.4%). While HCWs with hypertension and diabetes mellitus experienced more adverse effects, this association was not statistically significant. Cardiac adverse effects were reported in 13 cases (10.5%); however, no significant cardiovascular complications were observed.
conclusionsThis study found a higher occurrence of adverse effects among female participants, though previous research does not provide conclusive evidence for this finding. The incidence of gastrointestinal side effects was consistent with other studies on HCQ prophylaxis among HCWs. Although HCWs with hypertension and diabetes mellitus experienced more adverse effects, these were not statistically significant. No serious cardiovascular effects were observed. Given the evolving landscape of COVID-19 treatment and prevention, further large-scale trials are necessary to establish the safety and efficacy of HCQ prophylaxis among HCWs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.